An anti-TL1A monoclonal antibody called tulisokibart may help people with moderate to severe ulcerative colitis achieve ...

A research team led by Junior Associate Professor Kazuo Takayama, from the Department of Cell Growth and Differentiation, ...

Irrational antibiotic use damages mucus barrier, leading to intestinal inflammation, as shown in recent Science Advances ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've ...

Pseudopolyps ocurr due to the inflammation related to Crohn's disease or ulcerative colitis. Learn what pseudopolyps on ...

Researchers from the University of San Diego engineered a microrobot inside a liquid pill, and it treated inflammatory bowel disease without the need for drugs. About 7 million worldwide have ...

Some of her go-to IBD accounts to follow on Instagram include @natalieannhayden, @betterbelliesbymolly (run by Dunham-Friel), ...

A new study found that the average frequency of your bowel movements could impact your microbiome and risk of chronic disease ...

Opioid use is more prevalent among individuals with vs without IBD, although not related to a psychiatric comorbidity.

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...

In a review of 32 mixed-type human studies, multinational researchers found a growing association between various classes of ...

Tulisokibart is a tumor necrosis factor (TNF)-like cytokine 1A (TL1A) monoclonal antibody with a different mechanism of ...